ClinicalTrials.gov record
Completed Phase 2 Interventional

Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer

ClinicalTrials.gov ID: NCT00002889

Public ClinicalTrials.gov record NCT00002889. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

PROGNOSTIC SIGNIFICANCE OF ENDORECTAL MRI IN PREDICTING OUTCOME AFTER COMBINED RADIATION AND ANDROGEN SUPPRESSION FOR PROSTATE CANCER: A PROSPECTIVE PHASE II STUDY

Study identification

NCT ID
NCT00002889
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Enrollment
180 participants

Conditions and interventions

Interventions

  • flutamide Drug
  • goserelin Drug
  • leuprolide acetate Drug
  • low-LET photon therapy Radiation

Drug · Radiation

Eligibility (public fields only)

Age range
30 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 1997
Primary completion
Dec 31, 2003
Completion
May 31, 2009
Last update posted
Aug 17, 2023

1997 – 2009

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
UCSF Cancer Center and Cancer Research Institute San Francisco California 94115-0128
Walter Reed Army Medical Center Washington D.C. District of Columbia 20307-5000
University of Chicago Cancer Research Center Chicago Illinois 60637
Dana-Farber Cancer Institute Boston Massachusetts 02115
Joint Center for Radiation Therapy Boston Massachusetts 02215
St. Joseph's Hospital and Medical Center Paterson New Jersey 07503
Roswell Park Cancer Institute Buffalo New York 14263-0001
Memorial Sloan-Kettering Cancer Center New York New York 10021
Duke Comprehensive Cancer Center Durham North Carolina 27710
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center Winston-Salem North Carolina 27157-1082
Arthur G. James Cancer Hospital - Ohio State University Columbus Ohio 43210
Medical University of South Carolina Charleston South Carolina 29425-0721

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00002889, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 17, 2023 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00002889 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →